Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.64 |
| ▸ | CTSD | P07339 | 1/20 | 0.55 |
| ▸ | GPR52 | Q9Y2T5 | 1/20 | 0.54 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.54 |
| ▸ | STAT3 | P40763 | 1/20 | 0.51 |
| ▸ | MAOB | P27338 | 2/20 | 0.51 |
| ▸ | NPC1 | O15118 | 3/20 | 0.50 |
| ▸ | AR | P10275 | 2/20 | 0.50 |
| ▸ | HTT | P42858 | 2/20 | 0.50 |
| ▸ | CA12 | O43570 | 1/20 | 0.50 |
| ▸ | CA1 | P00915 | 1/20 | 0.50 |
| ▸ | CA2 | P00918 | 1/20 | 0.50 |
| ▸ | CA9 | Q16790 | 1/20 | 0.50 |
| ▸ | RAB9A | P51151 | 1/20 | 0.50 |
| ▸ | KCNK3 | O14649 | 1/20 | 0.49 |
| ▸ | KCNK9 | Q9NPC2 | 1/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31561740 | 1.00 | ABCG2 (0.64) | ABCG2CTSDGPR52ABCB1STAT3 | |
| SCHEMBL11600627 | 0.89 | ABCG2 (0.53) | ABCG2CTSDGPR52ABCB1STAT3 | |
| SCHEMBL31167606 | 0.86 | ABCG2 (0.77) | ABCG2CTSDGPR52ABCB1STAT3 | |
| SCHEMBL1697561 | 0.84 | ABCG2 (0.64) | ABCG2CTSDGPR52ABCB1STAT3 | |
| SCHEMBL29954715 | 0.84 | ABCG2 (0.64) | ABCG2CTSDGPR52ABCB1STAT3 | |
| SCHEMBL9178467 | 0.84 | ABCG2 (0.64) | ABCG2CTSDGPR52ABCB1STAT3 | |
| SCHEMBL28611217 | 0.83 | AKT1 (0.50) | ABCG2GPR52ABCB1HTTSMN1; SMN2 | |
| Acrylic Acid SCHEMBL27869582 | 0.83 | HTT (0.64) | ABCG2CTSDSTAT3NPC1HTT | |
| SCHEMBL15821571 | 0.82 | ABCG2 (0.62) | ABCG2CTSDGPR52ABCB1STAT3 | |
| SCHEMBL7828569 | 0.82 | ABCG2 (0.62) | ABCG2CTSDGPR52ABCB1STAT3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118179615-A | Preparation method of modified cation exchange resin for caprolactam purification | 衢州巨化锦纶有限责任公司 | 2024-06-14 | — | — | CN | claimed |
| CN-118179615-A | Preparation method of modified cation exchange resin for caprolactam purification | 衢州巨化锦纶有限责任公司 | 2024-06-14 | — | — | CN | disclosed |
| US-20170355997-A1 | METHODS AND COMPOSITIONS FOR TREATING OR PREVENTING PRURITIS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2017-12-14 | — | — | US | disclosed |
| US-9771592-B2 | Methods and compositions for treating or preventing pruritis | THE JOHNS HOPKINS UNIVERSITY (US) | 2017-09-26 | — | — | US | disclosed |
| US-20140303231-A1 | METHODS AND COMPOSITIONS FOR TREATING OR PREVENTING PRURITIS | THE JOHNS HOPKINS UNIVERSITY (US) | 2014-10-09 | — | — | US | disclosed |
| US-20120073001-A1 | METHODS AND COMPOSITIONS FOR TREATING OR PREVENTING PRURITIS | THE JOHNS HOPKINS UNIVERSITY (US) | 2012-03-22 | — | — | US | disclosed |
| WO-2009066298-A1 | NON-HYDROLYZABLE NUCLEOSIDE DI- OR TRI-PHOSPHATE DERIVATIVES AND USES THEREOF | BAR-ILAN UNIVERSITY (IL) | 2009-05-28 | — | — | WO | disclosed |
| US-20080027095-A1 | Use Of 3-Substituted-2-(Diphenylmethy)-1-Azabicyclo[2.2.2]Octanes For Treating Mrg-X1 Receptor Mediated Diseases | MERCK SHARP & DOHME CORP. | 2008-01-31 | — | — | US | disclosed |
| WO-2000032598-A9 | METHODS AND COMPOSITIONS FOR TREATING INFLAMMATORY DISEASES UTILIZING INHIBITORS OF TUMOR NECROSIS FACTOR ACTIVITY | STRUCTURAL BIOINFORMATICS INC (US) | 2000-11-30 | — | — | WO | disclosed |
| US-6080768-A | USEFUL IN THE TREATMENT OF ARTERIAL HYPERTENSION AND HEART FAILURE, RENAL INSUFFICIENCY, PERIPHERAL ARTERIOPATHIES AND CEREBROVASCULAR INSUFFICIENCIES | ZAMBON GROUP S.P.A. (IT) | 2000-06-27 | — | — | US | disclosed |
| WO-2000032598-A1 | METHODS AND COMPOSITIONS FOR TREATING INFLAMMATORY DISEASES UTILIZING INHIBITORS OF TUMOR NECROSIS FACTOR ACTIVITY | STRUCTURAL BIOINFORMATICS INC. (US) | 2000-06-08 | — | — | WO | disclosed |
| US-5747513-A | HYPOTENSIVE AGENTS, HEART FAILURE AND CEREBROVASCULAR INSUFFICIENCY | ZAMBON GROUP, S.P.A. (IT) | 1998-05-05 | — | — | US | disclosed |
| EP-0719252-B1 | DERIVATIVES OF 2-AMINO-1,2,3,4-TETRAHYDRONAPHTHALENE ACTIVE ON THE CARDIOVASCULAR SYSTEM | ZAMBON SPA (IT) | 1998-02-18 | — | — | EP | disclosed |
| EP-0719252-A1 | DERIVATIVES OF 2-AMINO-1,2,3,4-TETRAHYDRONAPHTHALENE ACTIVE ON THE CARDIOVASCULAR SYSTEM | ZAMBON GROUP S.p.A. (IT) | 1996-07-03 | — | — | EP | disclosed |
| WO-1995007885-A1 | DERIVATIVES OF 2-AMINO-1,2,3,4-TETRAHYDRONAPHTHALENE ACTIVE ON THE CARDIOVASCULAR SYSTEM | ZAMBON GROUP S.P.A. (IT) | 1995-03-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170355997-A1 | METHODS AND COMPOSITIONS FOR TREATING OR PREVENTING PRURITIS | ITCH, CCL11, CPA3 | ABCG2 1567/4885CTSD 432/4885GPR52 2418/4885 |
| US-20080027095-A1 | Use Of 3-Substituted-2-(Diphenylmethy)-1-Azabicyclo[2.2.2]Octanes For Treating Mrg-X1 Receptor Mediated Diseases | MRGPRX1, MRGPRX2, MRGPRX4 | ABCG2 4086/4885CTSD 4367/4885GPR52 31/4885 |
| US-20140303231-A1 | METHODS AND COMPOSITIONS FOR TREATING OR PREVENTING PRURITIS | ITCH, CCL11, CPA3 | ABCG2 1567/4885CTSD 432/4885GPR52 2418/4885 |
| US-20120073001-A1 | METHODS AND COMPOSITIONS FOR TREATING OR PREVENTING PRURITIS | ITCH, CCL11, CPA3 | ABCG2 1567/4885CTSD 432/4885GPR52 2418/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.